ALISON BIRTLE

Dr. Birtle is a consultant clinical oncologist at the Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Trust, Preston, UK, and an honorary senior lecturer (University of Manchester) specialising in the treatment of urological cancers.

She trained in oncology in London, completing her training on the academic urology unit at the Royal Marsden Hospital. Her MD thesis was in PSA negative prostate cancer at the Institute of Urology, University College London. She is an advisor to Macmillan on patient information for prostate, bladder and testicular tumours, and trustee and medical advisor to the patient lead information and advocacy group, Fight Bladder Cancer, and secretary to the British Uro Oncology Group.

She has published widely and lectures nationally and internationally. She has been clinical research lead for Lancashire and South Cumbria Cancer Research Network, and more recently, associate clinical lead for cancer research and since March 2018, specialty group lead for cancer research for North West Coast Clinical Research Network.

She is a former member of the National Institute for Health Research Prostate Clinical Study Group and stepped down as chair of the bladder/renal NIHR Clinical Study Group in 2018 after two terms. She remains a member of the Advanced Bladder Cancer Subgroup. She has been principal investigator and chief investigator on numerous urological clinical trials and is the Chief Investigator on the POUT trial.